Bliss Gvs Pharma Limited (IN:BLISSGVS)
:BLISSGVS
Top Page
Bliss Gvs Pharma Limited
(BLISSGVS)
Select Model
Select Model
Rating:74Outperform
Price Target:
₹262.00
▲(81.00% Upside)
Action:ReiteratedDate:01/07/26
The score is driven primarily by solid financial fundamentals—especially a strong, low-leverage balance sheet and improving profitability—supported by a clear technical uptrend. Valuation is reasonable on earnings but offers limited support from a very low dividend yield.
Positive Factors
Strong balance sheet
The company maintains a high equity ratio and low leverage, per the balance sheet summary. This structural capital strength supports investment, withstands demand shocks, and preserves strategic optionality for R&D, regulatory compliance costs, or tender-backed working capital over the next 2–6 months.
Negative Factors
Mixed cash flow performance
Variability in free cash flow growth reduces predictability of internal funding for capex, working capital and potential dividends. Even with healthy operating cash conversion, inconsistent FCF complicates strategic planning and may constrain reinvestment or buffer against cyclical demand shifts.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong balance sheet
The company maintains a high equity ratio and low leverage, per the balance sheet summary. This structural capital strength supports investment, withstands demand shocks, and preserves strategic optionality for R&D, regulatory compliance costs, or tender-backed working capital over the next 2–6 months.
Read all positive factors
Bliss Gvs Pharma Limited (BLISSGVS) vs. iShares MSCI India ETF (INDA)
Market Cap
₹24.79B
Dividend Yield0.28%
Average Volume (3M)104.36K
Price to Earnings (P/E)18.6
Beta (1Y)1.40
Revenue Growth7.51%
EPS Growth71.81%
CountryIN
Employees831
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)2.20
Shares Outstanding105,788,970
10 Day Avg. Volume77,644
30 Day Avg. Volume104,358
Financial Highlights & Ratios
PEG Ratio1.37
Price to Book (P/B)1.20
Price to Sales (P/S)1.56
P/FCF Ratio42.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bliss Gvs Pharma Limited Business Overview & Revenue Model
Company Description
Bliss GVS Pharma Limited develops, manufactures, and markets pharmaceutical formulations in India. It offers pharma products, including capsules, creams/gels/ointments, dry powder for injections and oral suspensions, effervescent tablets, eye/ear ...
How the Company Makes Money
Bliss GVS Pharma makes money primarily by selling pharmaceutical products. Its key revenue streams include (1) sales of finished dosage formulations (e.g., tablets and other formulations) under its own marketing and distribution channels, (2) expo...
Bliss Gvs Pharma Limited Financial Statement Overview
Summary
Income Statement
75
Positive
Balance Sheet
82
Very Positive
Cash Flow
68
Positive
| Breakdown | TTM | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.60B | 8.10B | 7.66B | 7.47B | 7.38B | 5.69B |
| Gross Profit | 3.95B | 3.96B | 2.49B | 3.50B | 3.47B | 2.40B |
| EBITDA | 2.07B | 1.27B | 1.49B | 1.35B | 762.37M | 1.27B |
| Net Income | 1.10B | 842.99M | 754.54M | 708.59M | 150.40M | 684.91M |
Balance Sheet | ||||||
| Total Assets | 14.00B | 13.01B | 12.14B | 11.57B | 11.09B | 10.77B |
| Cash, Cash Equivalents and Short-Term Investments | 2.01B | 1.41B | 1.41B | 684.11M | 1.35B | 616.64M |
| Total Debt | 524.91M | 881.04M | 998.40M | 1.02B | 1.09B | 1.22B |
| Total Liabilities | 2.32B | 2.09B | 2.11B | 2.39B | 2.62B | 2.49B |
| Stockholders Equity | 11.32B | 10.50B | 9.67B | 8.84B | 8.19B | 8.08B |
Cash Flow | ||||||
| Free Cash Flow | 483.04M | 298.48M | 1.24B | -594.86M | 614.77M | 548.45M |
| Operating Cash Flow | 775.52M | 1.06B | 1.52B | 343.13M | 1.35B | 639.69M |
| Investing Cash Flow | -272.20M | -754.41M | -1.33B | -77.51M | -929.75M | -469.91M |
| Financing Cash Flow | -448.06M | -303.45M | -208.93M | -249.38M | -237.30M | -207.98M |
Bliss Gvs Pharma Limited Technical Analysis
Positive
144.75
Price Trends
203.02
Positive
182.60
Positive
169.50
Positive
Market Momentum
4.95
Negative
61.17
Neutral
81.25
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:BLISSGVS, the sentiment is Positive. The current price of 144.75 is below the 20-day moving average (MA) of 213.58, below the 50-day MA of 203.02, and below the 200-day MA of 169.50, indicating a bullish trend. The MACD of 4.95 indicates Negative momentum. The RSI at 61.17 is Neutral, neither overbought nor oversold. The STOCH value of 81.25 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for IN:BLISSGVS.
Bliss Gvs Pharma Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | ₹24.79B | 18.57 | ― | 0.28% | 7.51% | 71.81% | |
71 Outperform | ₹16.16B | 27.93 | ― | 0.71% | 19.34% | 9.32% | |
67 Neutral | ₹12.47B | 28.83 | ― | 1.24% | 24.60% | 153.56% | |
64 Neutral | ₹10.62B | 17.72 | ― | ― | 56.41% | 90.24% | |
61 Neutral | ₹12.15B | 38.81 | ― | 0.44% | -3.84% | 86.82% | |
53 Neutral | ₹9.82B | 20.91 | ― | 0.24% | 13.04% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
IN:BLISSGVS
Bliss Gvs Pharma Limited
234.30
118.27
101.94%
IN:BAJAJHCARE
Bajaj Healthcare Ltd
311.05
-257.56
-45.30%
IN:HESTERBIO
Hester Biosciences Limited
1,427.90
-220.88
-13.40%
IN:JAGSNPHARM
Jagsonpal Pharmaceuticals Ltd.
186.20
-13.82
-6.91%
IN:SYNCOMF
Syncom Formulation (India) Ltd.
11.30
-4.83
-29.94%
IN:WINDLAS
Windlas Biotech Ltd.
763.50
-157.54
-17.10%
Bliss Gvs Pharma Limited Corporate Events
Bliss GVS Pharma bolsters board with two new independent directors
Apr 3, 2026
Bliss GVS Pharma Limited has strengthened its board oversight by appointing Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah as additional non-executive independent directors for a five-year term starting April 3, 2026. The appointments, re...
Bliss GVS Pharma Adds Two Independent Directors to Strengthen Board Oversight
Apr 3, 2026
Bliss GVS Pharma Limited has strengthened its board by appointing Vijayanarayanan Mahadevan and Deepak Rameshchandra Shah as additional non-executive independent directors for a five-year term starting April 3, 2026. Both appointees bring extensiv...
Bliss GVS Pharma Adds New Step-Down Subsidiary in DR Congo to Deepen African Reach
Jan 27, 2026
Bliss GVS Pharma Limited has expanded its African presence through its Singapore-based wholly owned subsidiary, Bliss GVS International PTE Ltd, which has incorporated a new step-down wholly owned subsidiary, THERALIFE PHARMA RDC PRIVATE LIMITED, ...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.